Cefiderocol for Severe Carbapenem-Resistant A. baumannii Pneumonia: Towards the Comprehension of Its Place in Therapy.
Antibiotics (Basel)
; 11(1)2021 Dec 21.
Article
in English
| MEDLINE | ID: covidwho-1636790
ABSTRACT
Cefiderocol use in A. baumannii pneumonia still represents an important matter of debate. The aim of this study is to describe 13 cases of carbapenem-resistant A. baumannii (CRAB) pneumonia treated with cefiderocol in real-life practice. We retrospectively included patients with CRAB pneumonia hospitalized at Fondazione Policlinico Universitario Agostino Gemelli Hospital treated with cefiderocol either in the general ward or the intensive care unit. A total of 11 patients out of 13 had ventilator-associated pneumonia caused by CRAB, and 12/13 patients had polymicrobial infection. We found a 30-day success rate of 54%. Cefiderocol may have a role when facing severe XDR A. baumannii pneumonia. Future studies are warranted to better define its place in therapy in CRAB infections.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Language:
English
Year:
2021
Document Type:
Article
Affiliation country:
Antibiotics11010003
Similar
MEDLINE
...
LILACS
LIS